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Background: An in vivo animal study and a prospective clinical study have indicated that bone marrow aspirate
(BMA) augments spinal arthrodesis. However, there is no quantified data to explain why fusion rate can be
augmented by BMA in lumbar posterolateral fusion.
Methods: To analyze the proportion of mesenchymal stem cells (MSCs) and osteogenic factors in human BMA and
peripheral blood (PB) of the same patient. Autologous BMA and PB from the patients were analyzed by flow cytometry
(FACS) using cell markers for MSCs. The osteogenic potential of MSCs was determined by alkaline phosphatase (ALP)
activity and calcium level quantification. Proteomics were used for the qualitative and quantitative mapping of the whole
proteome from BMA and PB plasma. The mass-to-charge ratio was calculated by time-of-flight mass spectrometry
(TOF-MS). The overexpression of protein was confirmed using Western blot analysis.
Results: The proportion of MSCs (CD34−/CD29+/CD105+) was higher in the BMA than that in the PB. Colony-forming
cell (CFC) assays suggested that fewer colonies were formed in PB cultures than in BMA culture. There was no significant
difference in the osteogenic potential of the MSCs between the PB and BMA. Proteomic mass spectrometry assays
suggested that the levels of catalase (osteoclast inhibitor) and glutathione peroxidase 3 (osteogenic biomarker) were
higher in the BMA than those in the PB, and this was confirmed by Western blot analysis.
Conclusions: The proportions of MSCs and osteogenic factors were higher in the BMA than in the PB. This may
explain why fusion rate can be augmented by BMA in lumbar posterolateral fusion.
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Thus far, autologous bone graft is the gold standard for
spinal fusion. Autologous cancellous bone harvested
from the ilium is commonly used in intertransverse
fusion of the lumbar spine. However, the incidence of
complications associated with harvesting bone from the
posterior iliac crest is significant. Various graft substi-
tutes or autograft extenders have become available or* Correspondence: chenwenj@adm.cgmh.org.tw
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[1,2], ceramics [3,4], demineralized bone matrix (DBM)
[5,6], and cultured stem cells [7]. Some of these substi-
tutes function as osteoconductors or as osteoinductors
in the process of osteogenesis.
Bone marrow aspirate (BMA) is harvested percutan-
eously from a cancellous-rich site such as the iliac crest,
proximal tibia, or calcaneus utilizing a bone marrow needle
and large-gauge syringe. Animal studies have proven that
BMA exhibits osteopromotive properties that promote
spinal fusion due to the presence of osteoprogenitor cells
and BMPs [8,9]. Our previous prospective clinical study
indicated that BMA augments spinal arthrodesis [10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Mesenchymal stem cells (MSCs) exhibit multipotent
differentiation potential, and have been shown to give
rise to different mesodermal cell lineages including oste-
oblasts, chondroblasts, and adipocytes [11]. MSCs have
to be plastic-adherent when maintained under standard
culture conditions. MSCs express CD73, CD90, and
CD105 and lack expression of the hematopoietic lineage
markers c-kit, CD14, CD11b, CD34, CD45, CD19, CD79α,
and human leukocyte antigen (HLA)-DR [12]. The aim of
this study was to analyze the proportion of MSCs in human
BMA. These factors in the PB of the same patient were also
evaluated and compared with the BMA.
Human plasma is easily obtainable and clinically valu-
able [13]. Plasma components derived from tissues and
organs vary in concentration by at least nine to ten
orders of magnitude [14]. Two-dimensional gel electro-
phoresis (2-DE) is a reliable method to quickly resolve
small quantities of proteins into hundreds of protein
spots with definite molecular weights and pIs, and can
allow for the comparison of protein intensity between sam-
ples. With the help of MALDI-TOF MS for rapid protein
identification, qualitative and quantitative changes of pri-
mary gene products and post-translational modifications
(PTMs) can be monitored [15,16]. For an identified osteo-
genic marker to be clinically useful, it should be measurable
in body fluid samples.
In this study, we analyzed the proportion of MSCs,
fibroblast colony-forming units (CFU-F) assay, and the
osteogenic potential of MSCs and investigated the differ-
ences between human BMA and PB. Proteomic analysis
was used to identify the proteins differently expressed in
BMA compared to PB and the findings were confirmed
by Western blotting. These findings may explain why
fusion rate can be augmented by BMA in lumbar pos-
terolateral fusion.
Materials and methods
We harvested the bone marrow aspirate (BMA) and per-
ipheral blood (PB) from 14 patients (64.1 ± 9.9 years old)
who received total discectomy and posterior lumbar inter-
body fusion with cages. A study design table is shown in
Table 1. The experimental protocol was approved by the
Human Subjects Institutional Review Board at the Chang
Gung Memorial Hospital.
Surgical procedures
During the operation, the patients were put in a prone
position over the four-poster frame. The skin, overlying
fascia, and musculature were opened to explore the pos-
terior elements of the lumbosacral spine and the extent
of the wound depending on the number of the levels of
stenosis and instability was treated. After finishing theposterior lumbosacral decompression procedure, the
right iliac crest close to the posterior superior iliac spine
was explored. The outer cortex was exposed by subper-
iosteal dissection and a 3 × 3-cm hole was created by
osteotomy. During bone graft harvesting, 10 ml of BMA
was aspirated and collected in a heparin-rinsed syringe.
Flow cytometry analysis for phenotyping of MSCs
Under sterile conditions, 1 ml of BMA or PB was col-
lected into a heparin-rinsed syringe. Two ml of 1X BD
Pharm Lyse™ lysing solution (Becton Dickinson, Franklin
Lakes, NJ, USA) was then added to each tube containing
up to 200 μl of a whole blood plus anti-CD29 FITC-
conjugated, anti-CD34 RPE conjugated and anti-CD105
Alexa Fluro-conjugated Ab (AbD Serotec, Oxford, UK)
mixture and incubated at room temperature, protected
from light, for 15 min. Cell suspensions were washed, cen-
trifuged, suspended, and analyzed on a FACS Calibur flow
cytometer with CellQuest software (Becton Dickinson).
Isolation of MSCs from BMA and peripheral blood
Under sterile conditions, 10 ml of BMA or PB was
collected into a heparin-rinsed syringe. The sample was
washed with PBS. Cells were recovered after centrifuga-
tion at 600 g for 10 min. Up to 2 × 108 of nucleated cells
in 5 ml of DPBS were loaded onto 25 ml of Percoll
cushion (Pharmacia Biotech, Piscataway, NJ, USA) of a
density of 1.073 g/ml in a 50-ml conical tube. Cell separ-
ation was accomplished by centrifugation at 1,100 g for
40 min at 20°C. The nucleated cells were collected from
the interface, diluted with two volumes of PBS, and col-
lected by centrifugation. The cells were then re-suspended,
counted, and plated at 105 cells in T-75 flasks (Coring, MA,
USA). The cells were maintained in complete medium
(DMEM-low glucose) (Gibco, Gran Island, NY, USA)
containing 10% fetal bovine serum (FBS) and antibiotics
(mixture of 100 units/ml of penicillin and 100 μg/ml of
streptomycin) (Gibco) at 37°C in a humidified atmosphere
of 5% CO2 and 95% air. After 4 days of primary culture, the
non-adherent cells were removed by changing the medium.
The medium was changed every 3 days thereafter. MSCs
grow as symmetrical colonies and were subcultured at 10
to 14 days.
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After the BMA or PB was enriched with Percoll [11],
107 mononuclear cells were plated in a 100-mm dish,
cultured for 2 weeks at 37°C in 5% humidified CO2 at-
mosphere, fixed with methanol at −20°C for 5 min, and
finally stained with Giemsa for counting. The number of
colonies was determined by image analysis of each dish
with Imagine-Pro version 5 software (Media Cybernetics,
Rockville, MD, USA).Alkaline phosphatase (ALP) activity measurement
MSCs from PB or BMA were cultured in complete
medium or induction medium (consisting of complete
medium supplemented with 10−9 M dexamethasone
20 mM β-glycerol phosphate and 50 μg/ml ascorbate-2-
phosphate) to measure the activity of ALP activity. At 4,
8, 12, and 16 days after culture, the culture medium was
withdrawn and the dish was washed twice with 10 ml of
Tyrode's balanced salt solution. A 10-ml aliquot of
ALP substrate buffer (50 mM glycine, 1 mM MgCl2,
pH 10.5), containing the soluble chromogenic ALP sub-
strate (2.5 mM p-nitrophenyl phosphate), was added at
room temperature. During incubation, cell-surface ALP
converts p-nitrophenyl phosphate into p-nitrophenol
and changes to a yellowish color. Twenty minutes after
addition of the substrate, 1 ml of the buffer was removed
from the culture and mixed with 1 ml of 1 N NaOH
to stop the reaction. The absorbance of the mixture
was read in triplicate on an ELISA MRX plate reader
(Dynatech Labs, USA) at 405 nm. The DNA content wasFigure 1 Flow cytometry analysis of MSC-like cells from PB and BMA.
was significantly lower than that in the BMA (t test, p < 0.01, n = 4).determined by DNAzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's instructions.
Enzyme activity was expressed as nmol p-nitrophenol/
min/μg DNA.
Calcium level quantification
MSCs from PB or BMA were cultured in induction
medium for 21 days. The culture dishes were rinsed
twice with Tyrode's balanced salt solution and then
poured into a 50-ml tube containing 10 ml of 0.5 N
HCl. Calcium was extracted from the cells by shaking
for 24 h at 4°C. Cellular debris was centrifuged and the
calcium in the supernatant was measured quantitatively
by a QuantiChrom™ calcium assay kit (BioAssay Systems,
Hayward, CA, USA) according to the manufacture'st in-
struction. Absorbance of the samples was measured on a
MRX multiplate reader (Dynatech Labs, USA) at 570 nm
for 5 to 10 min after the addition of the pertinent reagents.
DNA content was determined by DNAzol reagent (Invitro-
gen) according to the manufacture's protocol description.
Total calcium was calculated from standard curves of
solutions prepared in parallel with the experiments and
expressed as μg Ca/μg DNA.
Two-dimensional gel electrophoresis and silver staining
Six serum samples from PB or BMA for proteomic analysis
were collected. To improve the performance of the analysis
of the serum samples, albumin and immunoglobulin G
in the collected serum samples were depleted using an
albumin and IgG removal kit (Depletion Spin Trap, GEThe proportion of CD34−/CD29+/CD105+-nucleated cells in the PB
Figure 2 Fibroblast-colony-forming units (CFU-F) assay. Fewer
colonies were formed in the PB cultures than in BMA cultures
(t test, p < 0.01, n = 4).
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UK) according to the manufacturer's instructions. The
procedures for 2-DE gel running, staining, and imaging
were as previously described [17-19]. Briefly, aliquots
in sample buffer (7 M urea, 2 M thiourea, 4.5%
CHAPS, 100 mM DTE, 40 mM Tris, pH 8.8) were
applied to immobilized pH 3 to 10 nonlinear gradient
strips (Amersham Biosciences, Uppsala, Sweden). IEF
was performed at 80,000 Vh. The second dimension
was analyzed on 9% to 16% linear gradient polyacryl-
amide gels at constant 40 mA per gel for approximately
5 h. Proteins resolved by 2-DE were visualized by silver
staining as previously described [17-19]. Briefly, the
gels were fixed in 30% methanol for 15 min and then
subjected to washing with water, followed by 2 min inFigure 3 Alkaline phosphatase (ALP) activity measurement. There was
complete medium culture in both PB and BMA (t test, p < 0.01, n = 3). Ther
BMA in complete medium or induction medium culture in each time poinsodium thiosulfate (0.8 mM), then washing again with
water and subsequently equilibrated with 0.2% w/v sil-
ver nitrate for 25 min. The gels were then rinsed three
times with water and developed in 3% sodium carbon-
ate containing 0.04% v/v formaldehyde (37% solution).
The reaction was stopped with 40 mM EDTA and the
gels were washed three times with water. Finally, the
gels were scanned and the images analyzed using
Image Master 2D software, version 4.01.
In-gel digestion of proteins and mass spectrometric
analysis
More than 1.5-fold increased or decreased silver-
stained spots were excised and in-gel digested with trypsin
according to procedures described previously [17-19].
Briefly, the gels were destained by 1% potassium ferri-
cyanide and 1.6% sodium thiosulfate (Sigma, St. Louis,
MO, USA). The proteins were then reduced with
25 mM NH4HCO3 containing 10 mM DTT (Biosynth,
Switzerland) at 60°C for 30 min and alkylated with 55 mM
iodoacetamide (Amersham Biosciences, Amersham,
Buckinghamshire, UK) at room temperature for 30 min.
After reduction and alkylation, the proteins were digested
with trypsin (Promega, Madison, WI, USA) (20 mg/ml) at
37°C overnight. After digestion, the tryptic peptides were
acidified with 0.5% TCA and loaded onto an MTP Anchor
Chip™ 600/384 TF (Bruker Daltonik GmbH, Bremen,
Germany). MALDI-TOF MS analysis was performed on
an Ultraflex™ MALDI-TOF mass spectrometer (Bruker
Daltonik). Mono-isotopic peptide masses were assigned
and used for database searches with the MASCOT search
engine (http://www.matrixscience.com) (Matrix Science,
London, UK).higher ALP activity in the induction medium culture than in the
e were no significant differences in ALP activity between the PB and
t shown (t test, p > 0.05, n = 3).
Figure 4 Calcium level quantification. There was no significant
difference in calcium level between the PB and BMA (t test, p > 0.05,
n = 3).
Figure 5 Protein profiling of BMA and PB specimens. (A) Proteins (150 mg
that had more than a 1.5-fold increase or decrease in silver staining were excise
at higher expression levels and 5 at lower expression levels in the BMA than in
and Gpx) from 2-D gels.
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Twelve serum samples from PB or BMA were collected for
Western blotting. The protein content was quantitated
using a protein assay kit (Pierce Biotechnology, Rockford,
IL, USA), separated by 6% SDS-PAGE for catalase and 10%
for glutathione peroxidase and β-actin, and transferred onto
membranes using a transfer unit (Bio-Rad, Hercules, CA,
USA). After blocking, the membranes were incubated with
1,000-fold diluted rabbit antibodies against catalase and
glutathione peroxidase (Abcam, Cambridge, UK) or mouse
antibodies against β-actin (Millipore, Temecula, CA, USA).
After washing, the membranes were further incubated for
2 h with 10,000-fold goat anti-mouse IgG (Calbiochem,
Millipore, Billerica, MA, USA) or goat anti-rabbit IgG
(Millipore) conjugated to horseradish peroxidase. The
membranes were then washed and rinsed with ECL
detection reagents (Amersham Pharmacia Biotech,
Amersham, Buckinghamshire, UK). The band images
were photographed using ECL Hyperfilm (Amersham).) were subjected to 2-DE (pH 3 to 10) and detected by silver staining. Spots
d and in-gel digested with trypsin. At least 11 protein spots were detected
the PB. (B) Cropped images showing the two selected proteins (catalase
Table 2 2-DE and MALDI-TOF MS identification of proteins that are differentially expressed in BMA and PB
Spot Protein name Mr pI Scorea Sequence coverageb (%) Trend
1 Hemoglobin subunit beta 16,102 6.75 68 57 BMA > PB
2 Catalase 59,947 6.9 206 53 BMA > PB
3 Ferritin light chain 20,064 5.51 142 63 BMA > PB
4 Flavin reductase 22,219 7.13 179 89 BMA > PB
5 Protein S100-A8 10,885 6.51 103 67 BMA > PB
6 Complement C3 188,569 6.02 66 11 BMA > PB
7 Fibrinogen beta chain 56,577 8.54 148 51 BMA > PB
8 Hemopexin 52,385 6.55 121 41 BMA < PB
9 Serotransferrin 79,280 6.81 92 25 BMA < PB
10 Transthyretin 15,991 5.52 155 73 BMA > PB
11 Clusterin 53,031 5.89 108 41 BMA > PB
12 Apolipoprotein A-I 30,759 5.56 113 49 BMA < PB
13 Peroxiredoxin-2 22,049 5.66 181 72 BMA > PB
14 Leucine-rich alpha-2-glycoprotein 38,382 6.45 89 42 BMA < PB
15 Fibrinogen gamma chain 52,106 5.37 131 48 BMA < PB
16 Glutathione peroxidase 25,765 8.26 67 39 BMA > PB
aThe MASCOT search score of identified proteins is shown; b the percentage of sequence coverage (Seq Cov) of matched peptides in the identified protein.
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MSCs (CD34−/CD29+/CD105+) isolated from PB and BMA
The proportion of CD34−/CD29+/CD105+-nucleated cells
in the PB was significantly lower than that in the BMA
(Figure 1, 0.06% ± 0.03% vs. 0.24% ± 0.06%, p < 0.01, n = 4).
Colony-forming units assay
To determine the clonogenic potential of MSCs, colony-
forming units (CFU-F) assays were performed after
2 weeks of culture. The mean colony-forming efficiency
was 1.8 ± 0.9 mononuclear cells for the PB and 35.8 ± 9.1
mononuclear cells for the BMA. Fewer colonies were
formed in the PB cultures than in the BMA cultures
(Figure 2, p < 0.01, n = 4).
Alkaline phosphatase activity measurement
For the PB group, alkaline phosphatase (ALP) activity
measured in the complete medium was 13.2 ± 4.1, 15.1 ±
7.2, 18.3 ± 6.7, and 17.1 ± 5.1 nmol p-nitrophenol/min/
μg DNA after 4, 8, 12, and 16 days, respectively. ALP
activity measured in the induction medium was 51.5 ±
12.2, 66.5 ± 17.2, 162.7 ± 22.4, and 138.3 ± 23.5 nmol
p-nitrophenol/min/μg DNA after 4, 8, 12, and 16 days,
respectively. There was higher ALP activity in the induc-
tion medium than in complete medium culture in each
time point showed (Figure 3, p < 0.01, n = 3).
For the BMA group, ALP activity measured in the
complete medium was 15.2 ± 5.1, 17.2 ± 6.9, 18.6 ± 5.2,
and 16.4 ± 4.3 nmol p-nitrophenol/min/μg DNA after 4,8, 12, and 16 days, respectively. ALP activity measured
in the induction medium was 56.5 ± 16.2, 62.9 ± 115.4,
160.1 ± 33.9, and 143.2 ± 25.2 nmol p-nitrophenol/min/
μg DNA after 4, 8, 12, and16 days, respectively. There
was higher ALP activity in the induction medium than in
the complete medium culture at each time point (Figure 3,
p < 0.01, n = 3). However, there was no significant difference
between the PB and BMA in complete medium or induc-
tion medium culture in each time point showed (Figure 3,
p > 0.05, n = 3).
Calcium level quantification
The calcium level was 69 ± 18.5 μg Ca/μg DNA for the
PB group and 72.3 ± 16.4 μg Ca/μg DNA for the BMA
group. There was no significant difference between the
PB and BMA in calcium level (Figure 4, p > 0.05, n = 3).
Protein profiles of BMA and paired PB
In the proteins extracted from the paired specimens, at
least 11 protein spots were detected at higher expression
levels and 5 at lower expression levels in the BMA than
in the PB (Figure 5a). MALDI-TOF MS was used to
identify the proteins corresponding to these 16 spots,
and the relative levels of these proteins between the
BMA and PB were quantitated by image analysis
(Table 2). Although other spots also showed different
intensities between the BMA and PB in 2-DE, they
could not be definitively identified by MS. We thus fo-
cused on the 16 spots that showed differences in inten-
sity and could be unequivocally identified by MS. At
Figure 6 Mass spectrometric analysis of the protein spots. Protein spots of catalase (A) and Gpx (B) were picked, in-gel digested with trypsin,
and analyzed by MALDITOF MS. The matched peptides from mass spectrometric analysis of both spots to the amino acid sequence of human
catalase and Gpx are underlined and in bold.
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Figure 7 Western blot analysis of catalase and Gpx in BMA and
PB. The protein levels of catalase and glutathione peroxidase in
the BMA were significantly higher than those in the PB. The level
of β-actin in each sample detected by Western blot was used as a
loading control.
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and there were higher catalase (osteoclast inhibitor)
and glutathione peroxidase 3 (osteogeneic biomarker)
content in the BMA than in the PB (Figure 5b). The
identities of these two protein spots were confirmed by
MALDI-TOF MS and shown in Figure 6.
Western blot analysis of proteins expression in BMA and PB
To confirm the data obtained from 2-DE analysis, the
serum was detected by Western blotting with specific
antibodies. Our results revealed that the protein levels of
catalase and glutathione peroxidase in the BMA were
significantly higher than those in the PB (Figure 7).
Discussion
Morphologically, no specific characteristics distinguish
MSCs from other nucleated cells within BMA or PB. To
distinguish MSCs, specific markers reacting with cell re-
ceptor sites instead must be identified. Specific monoclo-
nal antibodies react with molecules on specific cell
surfaces and can be used to identify the protein clusters
for the markers which can facilitate the identification, iso-
lation, and study of stem cells. Multiple surface markers
have been associated with stem cells including CD29,
CD34, CD106, CD105, and CD309 (KDR) [20-22].
The use of FACS has the potential to identify MSCs more
precisely. CD29 and CD105 are expressed by MSCs [11,23]
whereas CD34 is expressed by hematopoietic stem cells
and capillary endothelial progenitor cells but not MSCs
[11,20,23]. In the present study, the results suggested that
the proportion of MSC-like cells (CD34−/CD29+/CD105+)
in the PB was significantly lower than that in the BMA,
which provides quantified information for the osteopromo-
tive effects of BMA (Figure 1). In addition, CFU-F assays
also suggested that fewer colonies were formed in the PB
cultures than in BMA cultures (Figure 2). CFU-Fs are
clearly indicative of cells capable of forming colonies and
are representative of the more highly proliferative cells inthese cultures [21]. Under proper experimental conditions,
BMA CFU-Fs are able to differentiate into bone, cartilage,
adipocytes, fibrous tissues, and hematopoietic supporting
tissues in vitro and in vivo [11,22]. In the present study, the
osteogenic potential of CFU-Fs was determined by ALP ac-
tivity (Figure 3) and calcium level (Figure 4), and no signifi-
cant differences between the PB and BMA were found.
Although, fewer colonies were formed in the PB cultures
than in BMA cultures (Figure 2), the CFU-Fs isolated from
these two groups had similar proliferation and differenti-
ation abilities.
Connolly et al. [24] clinically found the osteopromo-
tive effects of whole bone marrow when autologous
marrow was injected into a tibial defect site. Although
both blood and bone marrow can be immediately
harvested and used as autologous materials for osteo-
promotion, an in vivo animal study [9] showed that
BMA has a higher osteogenic potential than blood
when it is impregnated through β-tricalcium phosphate
(β-TCP), an osteoconductive scaffold. The authors have
previously reported on the use of BMA in combination
with the scaffold material at grafting sites and indicated that
BMA augments spinal arthrodesis [10]. The reason for this
difference may be the proportion of bone marrow MSCs in
BMA.
To find possible factors to gain new insight into the
mechanisms of bone formation and development, we
subjected proteins extracted from BMA specimens and
paired PB to 2-DE separation, silver staining, and
MALDI-TOF MS analysis (Figures 5 and 6). At least
two osteogenesis related proteins were found: there
were higher catalase and glutathione peroxidase 3
(Gpx 3) content in the BMA than in the PB. The pro-
tein level of catalase was significantly up-regulated in a
time-dependent manner during osteogenic differenti-
ation thus reduce the excess reactive oxygen species
(ROS) production to hamper the osteogenic differenti-
ation of MSCs [25]. In addition, catalase has been
reported to partially inhibit ascorbic acid-induced
osteoclastogenesis [26]. Selenite enhanced the gene
expression and activity of Gpx, reversed the decreased
total antioxidant capacity and reduced glutathione, and
against hydrogen peroxide-induced inhibition of osteo-
blastic differentiation of MSCs [27].
Aspiration of autogenous bone marrow cells from the
iliac crest is a simple and safe procedure that can be per-
formed with the patient under anesthesia and involves
little to no donor site morbidity. The use of such mater-
ial at bone-grafting sites has the potential to produce a
significant quantity of viable bone [10,28]. BMA may
have the ability to facilitate osteogenesis by acting as
both an osteoprogenitor and osteoinductor to supple-
ment the limited amount of available autologous bone
for multilevel spinal fusion.
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osteogenic factors were higher in the BMA than in the
PB. This may explain why fusion rate can be augmented
by BMA in lumbar posterolateral fusion. In the future,
we will evaluate whether the fusion rate of autogenous
laminectomy bone chips could be augmented by BMA
in a rabbit model.Conclusion
The proportions of MSCs and osteogenic factors were
higher in the BMA than those in the PB. This may
explain why fusion rate can be augmented by BMA in
lumbar posterolateral fusion.
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